INT108348

Context Info Confidence 0.68 First Reported 2003 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 10 Total Number 10 Disease Relevance 4.94 Pain Relevance 0.82

aging (Aqp2) plasma membrane (Aqp2) protein complex (Aqp2) transmembrane transport (Aqp2) lysosome (Aqp2) cytoplasm (Aqp2)

Anatomy Link Frequency urine 6 plasma 1 lumen 1 Aqp2 (Rattus norvegicus)

Pain Link Frequency Relevance Heat COX-2 inhibitor 10 99.54 cINOD 8 96.20 ischemia 11 92.04 medulla 4 56.24 anesthesia 15 50.00 antagonist 20 5.00 isoflurane 16 5.00 Inflammation 11 5.00 withdrawal 6 5.00 alcohol 4 5.00

Disease Link Frequency Relevance Heat Polyuria 13 99.90 Diabetes Insipidus 20 99.56 Cv Unclassified Under Development 8 92.04 INFLAMMATION 17 91.20 Injury 31 85.04 Chronic Renal Failure 522 83.32 Pressure And Volume Under Development 17 82.60 Reperfusion Injury 3 76.24 Renal Disease 23 66.16 Body Weight 10 60.80

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.

Positive_regulation (upregulation) of AQP2 associated with polyuria, diabetes insipidus and cox-2 inhibitor

1) Confidence 0.68 Published 2008 Journal Am. J. Physiol. Renal Physiol. Section Title Doc Link 18216147 Disease Relevance 0.74 Pain Relevance 0.33

Baseline urine osmolality was greater in the TD group than in the control and the TT groups, an effect associated with increased renal aquaporin 2 level.

Positive_regulation (increased) of aquaporin 2 in urine

2) Confidence 0.66 Published 2010 Journal J Biomed Sci Section Abstract Doc Link PMC2994366 Disease Relevance 0.33 Pain Relevance 0.08

The upregulation of AQP2 and NKCC2 in response to the COX-2 inhibitor may underlie the therapeutic mechanisms by which NSAIDs enhance antidiuresis in patients with NDI.

Positive_regulation (upregulation) of AQP2 associated with diabetes insipidus, cinod and cox-2 inhibitor

3) Confidence 0.49 Published 2008 Journal Am. J. Physiol. Renal Physiol. Section Abstract Doc Link 18216147 Disease Relevance 0.73 Pain Relevance 0.30

Interestingly, in a parallel study, we found that treatment with the AT1 receptor blocker candesartan in NaCl-restricted normal rats prevented the increase of the expression of inner medullary AQP2 and phosphorylated-AQP2 (AQP2 phosphorylated in the PKA-phosphorylation consensus site Ser-256) and the increase of urine concentration in response to the long-term dDAVP treatment (25).

Positive_regulation (increase) of AQP2 in urine

4) Confidence 0.47 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.69 Pain Relevance 0.03

Interestingly, in a parallel study, we found that treatment with the AT1 receptor blocker candesartan in NaCl-restricted normal rats prevented the increase of the expression of inner medullary AQP2 and phosphorylated-AQP2 (AQP2 phosphorylated in the PKA-phosphorylation consensus site Ser-256) and the increase of urine concentration in response to the long-term dDAVP treatment (25).

Positive_regulation (increase) of AQP2 in urine

5) Confidence 0.47 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.70 Pain Relevance 0.03

Interestingly, in a parallel study, we found that treatment with the AT1 receptor blocker candesartan in NaCl-restricted normal rats prevented the increase of the expression of inner medullary AQP2 and phosphorylated-AQP2 (AQP2 phosphorylated in the PKA-phosphorylation consensus site Ser-256) and the increase of urine concentration in response to the long-term dDAVP treatment (25).

Positive_regulation (increase) of AQP2 in urine

6) Confidence 0.47 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.69 Pain Relevance 0.03

Interestingly, in a parallel study, we found that treatment with the AT1 receptor blocker candesartan in NaCl-restricted normal rats prevented the increase of the expression of inner medullary AQP2 and phosphorylated-AQP2 (AQP2 phosphorylated in the PKA-phosphorylation consensus site Ser-256) and the increase of urine concentration in response to the long-term dDAVP treatment (25).

Positive_regulation (increase) of AQP2 in urine

7) Confidence 0.41 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.68 Pain Relevance 0.03

The concentration of AQP2 was not significantly changed during the urine concentrating test in Groups 3 and 4, but increased significantly in the other two groups.

Neg (not) Positive_regulation (increased) of AQP2 in urine

8) Confidence 0.36 Published 2010 Journal BMC Nephrol Section Body Doc Link PMC2965705 Disease Relevance 0.07 Pain Relevance 0

This results in an increased production of c-AMP, which through a cascade of intracellular reactions upregulate the AQP 2 water channels, and thereby promotes water transport from the tubular lumen to the cell.

Positive_regulation (upregulate) of AQP 2 in lumen

9) Confidence 0.29 Published 2010 Journal BMC Nephrol Section Body Doc Link PMC2965705 Disease Relevance 0.30 Pain Relevance 0

RESULTS: Increases in plasma AM levels were observed in parallel with increases in the levels of urinary AQP2/creatinine (Cr) before induction and 90 and 180 min after initiation of anesthesia.

Positive_regulation (increases) of AQP2 in plasma

10) Confidence 0.14 Published 2003 Journal Horm. Res. Section Body Doc Link 12566732 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.